Nanomedicines can be multifunctional drug delivery agents for cancer therapies. However, they have faced several challenges in clinical trials owing to poor targeting ability, insufficient tumor penetration, difficulty in synthesis and scale up, and limited understanding of interactions between a tumor and nanoparticles. In this regard, tumor muticomponent targeting drug delivery systems are a rational approach for developing tumor-site-specific therapeutics. One of the goals is to arrive at a ready-to-configure, combinatorial, reagent-free click-chemistry-based tumor multicomponent targeting nanoparticle library. The nanoparticles can be co-loaded with drugs, genes and imaging agents, surface decorated with varying targeting ligands that can home to varying tumors and/or tumor multicomponents. This library of nanocarriers could be utilized for early tumor diagnosis and therapy based on individual patient needs for personalized medicine, with a high degree of success in the clinic.

纳米药物可以是用于癌症治疗的多功能药物递送剂。然而，由于靶向能力差，肿瘤渗透性不足，合成和扩大规模困难以及对肿瘤与纳米颗粒之间相互作用的了解有限，它们在临床试验中面临一些挑战。在这方面，靶向肿瘤多组分药物递送系统是开发特定于肿瘤部位的治疗剂的合理方法。目标之一是获得一种易于配置的，组合的，无试剂的，基于点击化学的肿瘤多组分靶向纳米颗粒文库。纳米颗粒可以与药物，基因和显像剂共同负载，表面用变化的靶向配体修饰，所述靶向配体可以归巢于变化的肿瘤和/或肿瘤多组分。